ResMed Inc. (RMD) Key Metrics
RMD valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $33.61B
- Enterprise value
- $31.42B
- P/E (TTM)
- 22.9 10-yr median 37.7
- Forward P/E
- 18.5
- PEG ratio
- 1.29
- Price / sales
- 5.9 10-yr median 7.1
- Price / book
- 4.9 10-yr median 7.5
- EV / EBITDA
- 15.0 10-yr median 23.4
- Dividend yield
- 1.10% $2.64 a year
- Beta
- 0.75
RMD key metrics, FY2017–FY2026
Fiscal year ended June 30, 2026 · U.S. dollarsRMD valuation Price multiples at each fiscal year-end price.
RMD returns How much profit the business earns on the capital it uses.
RMD per-share figures Results divided by the shares outstanding at year-end.
RMD financial health Debt, liquidity and how easily interest is covered.
RMD efficiency & capital use Working capital cycle and where the cash goes.
RMD valuation history
RMD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RMD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RMD cash returned to shareholders
RMD price vs earnings per share
RMD key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $28.46B | $38.01B | $28.24B | $32.22B | $30.82B | $36.10B | $27.97B | $17.63B | $14.91B | $11.09B |
| Enterprise value | $27.82B | $37.66B | $28.88B | $33.57B | $31.47B | $36.60B | $28.80B | $18.76B | $15.01B | $11.56B |
| P/E ratio | 18.7 | 27.1 | 27.7 | 35.9 | 39.5 | 76.1 | 45.0 | 43.6 | 47.3 | 32.4 |
| Price / sales | 5.0 | 7.4 | 6.0 | 7.6 | 8.6 | 11.3 | 9.5 | 6.8 | 6.4 | 5.4 |
| Price / book | 4.3 | 6.4 | 5.8 | 7.8 | 9.2 | 12.5 | 11.2 | 8.5 | 7.2 | 5.7 |
| Price / free cash flow | 17.3 | 22.9 | 22.0 | 57.6 | 158.0 | 58.2 | 40.2 | 46.2 | 34.4 | 32.4 |
| Price / operating cash flow | 15.8 | 21.7 | 20.2 | 46.5 | 87.8 | 49.0 | 34.9 | 38.4 | 29.5 | 26.8 |
| EV / sales | 4.9 | 7.3 | 6.2 | 7.9 | 8.8 | 11.4 | 9.7 | 7.2 | 6.4 | 5.6 |
| EV / EBITDA | 12.9 | 19.7 | 18.8 | 24.7 | 26.7 | 33.2 | 29.1 | 26.6 | 22.1 | 20.3 |
| EV / free cash flow | 16.9 | 22.7 | 22.4 | 60.0 | 161.3 | 59.0 | 41.4 | 49.1 | 34.6 | 33.8 |
| Earnings yield | 5.4% | 3.7% | 3.6% | 2.8% | 2.5% | 1.3% | 2.2% | 2.3% | 2.1% | 3.1% |
| Free cash flow yield | 5.8% | 4.4% | 4.6% | 1.7% | 0.6% | 1.7% | 2.5% | 2.2% | 2.9% | 3.1% |
| Dividend yield | 1.2% | 0.8% | 1.0% | 0.8% | 0.8% | 0.6% | 0.8% | 1.2% | 1.3% | 1.7% |
| Shareholder yield (dividends + buybacks) | 3.7% | 1.6% | 1.5% | 0.8% | 0.8% | 0.6% | 0.8% | 1.3% | 1.7% | 2.6% |
| Share price at fiscal year-end | $194.88 | $258.00 | $191.42 | $218.50 | $209.63 | $246.52 | $192.00 | $122.03 | $103.58 | $77.87 |
| Per share | ||||||||||
| Revenue per share | $38.71 | $34.93 | $31.75 | $28.64 | $24.33 | $21.83 | $20.30 | $18.04 | $16.25 | $14.51 |
| Earnings per share | $10.43 | $9.51 | $6.92 | $6.09 | $5.30 | $3.24 | $4.27 | $2.80 | $2.19 | $2.40 |
| Operating cash flow per share | $12.36 | $11.89 | $9.50 | $4.70 | $2.39 | $5.03 | $5.51 | $3.18 | $3.51 | $2.91 |
| Free cash flow per share | $11.29 | $11.28 | $8.72 | $3.79 | $1.33 | $4.23 | $4.78 | $2.64 | $3.01 | $2.40 |
| Cash per share | $10.06 | $8.21 | $1.62 | $1.55 | $1.86 | $2.02 | $3.18 | $1.02 | $1.31 | $5.77 |
| Book value per share | $45.09 | $40.50 | $32.97 | $28.01 | $22.86 | $19.70 | $17.14 | $14.34 | $14.30 | $13.76 |
| Tangible book value per share | $18.97 | $16.67 | $10.41 | $5.47 | $7.33 | $3.86 | $1.09 | −$2.12 | $5.38 | $4.45 |
| Dividends per share | $2.39 | $2.11 | $1.91 | $1.75 | $1.67 | $1.55 | $1.55 | $1.47 | $1.39 | $1.31 |
| Capex per share | $1.07 | $0.61 | $0.78 | $0.91 | $1.06 | $0.80 | $0.73 | $0.54 | $0.50 | $0.50 |
| Debt per share | $5.65 | $5.78 | $5.92 | $10.71 | $6.24 | $5.42 | $8.92 | $8.80 | $1.95 | $9.08 |
| Shares outstanding | 146.1M | 147.3M | 147.6M | 147.5M | 147.0M | 146.5M | 145.7M | 144.5M | 144.0M | 142.5M |
| Change in shares outstanding | −0.9% | −0.1% | +0.1% | +0.3% | +0.4% | +0.5% | +0.8% | +0.3% | +1.1% | +0.6% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 24.3% | 25.9% | 22.7% | 24.0% | 25.0% | 17.6% | 27.2% | 19.6% | 15.7% | 18.7% |
| Return on invested capital (ROIC) | 26.2% | 25.3% | 19.4% | 19.4% | 22.0% | 14.4% | 21.0% | 16.9% | 14.3% | 15.2% |
| Return on assets (ROA) | 17.8% | 18.6% | 15.0% | 15.2% | 15.9% | 10.2% | 14.3% | 11.3% | 9.7% | 10.2% |
| Return on tangible assets | 29.6% | 30.0% | 28.8% | 26.2% | 27.7% | 19.7% | 27.6% | 23.4% | 17.7% | 16.0% |
| Free cash flow margin | 29.2% | 32.3% | 27.5% | 13.2% | 5.5% | 19.4% | 23.5% | 14.6% | 18.5% | 16.6% |
| Income quality (OCF / net income) | 1.19 | 1.25 | 1.37 | 0.77 | 0.45 | 1.55 | 1.29 | 1.13 | 1.60 | 1.21 |
| Financial health | ||||||||||
| Total debt | $825.9M | $851.8M | $873.9M | $1.58B | $917.5M | $793.7M | $1.30B | $1.27B | $281.5M | $1.29B |
| Cash & short-term investments | $1.47B | $1.21B | $238.4M | $227.9M | $273.7M | $295.3M | $463.2M | $147.1M | $188.7M | $821.9M |
| Net debt | −$643.3M | −$357.6M | $635.6M | $1.35B | $643.8M | $498.4M | $836.1M | $1.12B | $92.8M | $471.7M |
| Debt / equity | 0.13 | 0.14 | 0.18 | 0.38 | 0.27 | 0.28 | 0.52 | 0.61 | 0.14 | 0.66 |
| Debt / assets | 0.09 | 0.10 | 0.13 | 0.23 | 0.18 | 0.17 | 0.28 | 0.31 | 0.09 | 0.37 |
| Net debt / EBITDA | −0.30 | −0.19 | 0.41 | 0.99 | 0.55 | 0.45 | 0.84 | 1.59 | 0.14 | 0.83 |
| Current ratio | 3.10 | 3.44 | 2.59 | 3.12 | 2.80 | 1.73 | 2.53 | 2.06 | 2.08 | 4.57 |
| Quick ratio | 2.42 | 2.53 | 1.69 | 1.81 | 1.72 | 1.23 | 1.84 | 1.43 | 1.56 | 3.82 |
| Interest coverage | 65.7 | 133.7 | 28.9 | 23.9 | 44.8 | 37.7 | 20.1 | 16.0 | 19.1 | 15.1 |
| Working capital | $2.93B | $2.49B | $1.45B | $1.61B | $1.24B | $663.0M | $920.7M | $589.4M | $554.5M | $1.28B |
| Invested capital | $5.94B | $5.61B | $5.50B | $5.48B | $4.00B | $3.38B | $3.33B | $3.20B | $2.15B | $2.43B |
| Tangible asset value | $2.77B | $2.46B | $1.54B | $807.3M | $1.08B | $565.2M | $158.5M | −$306.2M | $774.9M | $633.6M |
| Net current asset value | $1.94B | $1.30B | $349.4M | −$254.0M | $196.4M | −$267.7M | −$566.9M | −$890.1M | $60.8M | $135.8M |
| Graham number | $102.86 | $93.08 | $71.64 | $61.93 | $52.21 | $37.90 | $40.58 | $30.06 | $26.56 | $27.28 |
| Graham net-net per share | $2.32 | $1.42 | −$4.95 | −$9.27 | −$4.47 | −$5.80 | −$7.30 | −$9.12 | −$2.22 | −$1.50 |
| Capital allocation | ||||||||||
| Dividends paid | $349.7M | $310.9M | $282.3M | $258.3M | $245.3M | $226.7M | $225.1M | $211.7M | $199.5M | $186.3M |
| Share buybacks (net) | $700.0M | $300.0M | $150.0M | $0 | $0 | $0 | $0 | $22.8M | $53.8M | $102.1M |
| Dividend payout ratio | 23.0% | 22.2% | 27.7% | 28.8% | 31.5% | 47.8% | 36.2% | 52.3% | 63.2% | 54.4% |
| Dividends + buybacks / free cash flow | 63.6% | 36.8% | 33.6% | 46.2% | 125.7% | 36.6% | 32.3% | 61.4% | 58.4% | 84.2% |
| Capex / revenue | 2.8% | 1.7% | 2.5% | 3.2% | 4.4% | 3.7% | 3.6% | 3.0% | 3.1% | 3.5% |
| Capex / operating cash flow | 8.7% | 5.1% | 8.2% | 19.3% | 44.4% | 15.9% | 13.2% | 16.8% | 14.1% | 17.3% |
| Capex / depreciation | 0.64 | 0.38 | 0.53 | 0.68 | 0.80 | 0.61 | 0.58 | 0.51 | 0.60 | 0.64 |
| Stock-based compensation / revenue | 1.8% | 1.8% | 1.7% | 1.7% | 1.8% | 2.0% | 1.9% | 2.0% | 2.1% | 2.2% |
| R&D / revenue | 6.7% | 6.4% | 6.6% | 6.8% | 7.1% | 7.0% | 6.8% | 6.9% | 6.6% | 7.0% |
| SG&A / revenue | 19.8% | 19.3% | 19.6% | 20.7% | 20.7% | 21.0% | 22.9% | 24.7% | 25.7% | 27.1% |
| Efficiency | ||||||||||
| Days sales outstanding | 65.4 | 64.8 | 60.1 | 55.4 | 61.3 | 62.8 | 61.9 | 70.9 | 72.9 | 73.5 |
| Days of inventory on hand | 155.3 | 152.7 | 163.6 | 170.2 | 141.1 | 117.5 | 112.9 | 105.5 | 100.2 | 104.0 |
| Days payables outstanding | 48.7 | 45.0 | 34.9 | 30.3 | 34.9 | 36.8 | 37.0 | 35.6 | 34.6 | 39.1 |
| Cash conversion cycle (days) | 172.1 | 172.5 | 188.8 | 195.3 | 167.4 | 143.5 | 137.8 | 140.8 | 138.5 | 138.4 |
| Receivables turnover | 5.58 | 5.63 | 6.08 | 6.59 | 5.96 | 5.81 | 5.90 | 5.15 | 5.01 | 4.96 |
| Payables turnover | 7.50 | 8.11 | 10.45 | 12.05 | 10.45 | 9.92 | 9.85 | 10.27 | 10.55 | 9.33 |
| Inventory turnover | 2.35 | 2.39 | 2.23 | 2.14 | 2.59 | 3.11 | 3.23 | 3.46 | 3.64 | 3.51 |
| Asset turnover | 0.66 | 0.68 | 0.69 | 0.71 | 0.73 | 0.69 | 0.68 | 0.73 | 0.72 | 0.61 |
| Average receivables | $1.01B | $914.0M | $771.1M | $640.4M | $600.6M | $549.9M | $501.6M | $506.1M | $467.1M | $416.3M |
| Average payables | $293.5M | $257.9M | $194.2M | $155.0M | $148.6M | $136.9M | $125.8M | $104.2M | $92.7M | $92.7M |
| Average inventory | $936.8M | $875.0M | $910.1M | $871.0M | $600.5M | $437.0M | $383.3M | $309.2M | $268.5M | $246.4M |
| Intangibles / total assets | 42.6% | 43.0% | 48.4% | 49.2% | 44.8% | 49.1% | 51.0% | 57.9% | 41.9% | 38.2% |
Computed from RMD's annual financial statements (latest annual report filed August 13, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RMD valuation and financial ratios
At the end of fiscal 2026 (June 30, 2026), ResMed traded at 18.7 times earnings, against a 10-year median of 37.7. Based on the latest twelve months, the trailing P/E is 22.9 and the forward P/E is 18.5. ResMed earned a return on equity of 24.3% and a return on invested capital of 26.2% in fiscal 2026. It ended the year with $825.9 million of debt and $1.5 billion in cash and short-term investments, a net cash position of $643.3 million. It returned $1.0 billion to shareholders: $349.7 million in dividends and $700.0 million in share buybacks, 64% of free cash flow.
See the RMD income statement, the RMD chart for price history, or the RMD stock overview for the latest quote and news.
RMD key metrics FAQ
What is ResMed's P/E ratio?
ResMed's trailing P/E ratio is 22.9 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 18.5. At the end of fiscal 2026 it was 18.7, compared with a 10-year median of 37.7.
What is ResMed's EV/EBITDA?
ResMed's enterprise value was 12.9 times EBITDA at the end of fiscal 2026 (enterprise value $27.8 billion, EBITDA $2.2 billion); the current EV/EBITDA is 15.0.
What is ResMed's return on equity?
ResMed's return on equity (ROE) was 24.3% in fiscal 2026: net income of $1.5 billion on average shareholders' equity of $6.3 billion.
What is ResMed's ROIC?
ResMed's return on invested capital was 26.2% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does ResMed have?
ResMed had total debt of $825.9 million at the end of fiscal 2026, a debt-to-equity ratio of 0.13 and more cash than debt.
What is ResMed's dividend yield?
ResMed's forward dividend yield is 1.10%. ResMed paid $349.7 million in dividends in fiscal 2026 ($2.39 per share), a payout ratio of 23.0%.
Does ResMed buy back its shares?
Yes. ResMed spent $700.0 million on net share repurchases in fiscal 2026 Shares outstanding changed −0.9% over the year, to 146.1M..
What is ResMed's free cash flow yield?
ResMed generated $1.6 billion of free cash flow in fiscal 2026, a free cash flow yield of 5.8% on its market value at year-end ($28.5 billion).
What is ResMed's current ratio?
ResMed's current ratio was 3.10 at the end of fiscal 2026: current assets were 3.10 times current liabilities.